Enliven Therapeutics Inc (ELVN) 銘柄情報

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancin... Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer. The Company focuses on addressing existing and emerging unmet needs with a precision oncology approach. The Company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, as well as pursuing several additional research stage opportunities. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). Its second product candidate, ELVN-002, is a potent, selective, and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against various HER2 mutations, including Exon 20 insertion mutations (E20IMs) in non-small cell lung cancer (NSCLC). 詳細を表示